(Q50587158)

English

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

scientific article published in February 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

interferon alfa

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

author name string

T Cotonat

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

J A Quiroga

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

J M López-Alcorocho

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

R Clouet

4

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

M Pardo

5

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

F Manzarbeitia

6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

V Carreño

7

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

language of work or name

0 references

publication date

1 February 2000

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

31

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

502-506

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Pilot study of ribavirin and interferon-beta for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

21 January 2018

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of hepatitis B virus precore variants in hepatitis B e antibody-positive patients treated with prednisone plus interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Trial of ribavirin for the treatment of HBsAg positive chronic liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Histopathological aspects of viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310234

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.510310234

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/10655277

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50587158&oldid=1612202421"